Background: Cell-derived microparticles (MPs) are important biomarkers in many facets of medicine. However, the MP detection methods used till date are costly and time consuming. The main aim of this study was to standardize an in-house clot based screening method for MP detection which would not only be specific and sensitive, but also inexpensive. Methods: Four different methods of MP assessment were performed and the results correlated. Using the flow cytometry technique as the gold standard, 25 samples with normal phosphatidylserine (PS) expressing MP levels and 25 samples with elevated levels were selected, which was cross checked by the commercial STA Procoag PPL clotting time (CT) assay. A simple recalcification time and an in-house clot assay were the remaining two tests. The in-house test measures the CT after the addition of calcium chloride to MP rich plasma, following incubation with Russell viper venom and phospholipid free plasma. Results: The CT obtained by the in-house assay significantly correlated with the results obtained by flow cytometry (R
Introduction
Cell-derived microparticles (MPs) are submicronic phospholipid vesicles; 0.1-1 μm in size; derived from cells of different types during activation or apoptosis. A proportion of MPs express phosphatidylserine (PS) and/or tissue factor on their surface giving them their prothrombotic nature. They also have other attributes like they are proinflammatory, pro-angiogenic or immunomodulatory and are associated with vascular dysfunction [1] .
The clinical significance of these procoagulant MPs could be diverse. There are many studies which show a strong association of elevated MPs with different thrombotic diseases [2] . Elevated MPs have been found in deep vein thrombosis, pulmonary embolism, stroke, coronary syndrome sepsis, disseminated intravascular coagulation, cardiovascular diseases as well as recurrent miscarriages and other poor obstetric outcomes [3] [4] [5] . A study done at our centre showed [6] , that elevated MPs at the start of pregnancy in such women with history of pregnancy loss decreased as anticoagulant therapy progressed and normalized in women who had live birth outcome, possibly as a result of anticoagulant treatment. Thus, MPs may serve as important biomarkers for monitoring anticoagulation therapy.
The best and the most common technique used for detection of MPs is flow cytometry [7, 8] . However, this method needs to be standardized properly to eliminate electronic noise. The reagents required for standardization and running the samples, are expensive. Though, the method not only gives you exact MP levels and their cellular origin, yet, it is a time consuming process and is not practical for small number of samples on a daily basis for immediate results. Also flow cytometry technique cannot detect functional activity of MPs, thus should be done in combination with functional assays. The enzyme linked immunosorbent assay [9] too cannot be used on a daily basis unless many samples have to be processed. The commercially available clot based assay for MPs, i.e. STA Procoag PPL is an efficient screening technique for MP analysis. The results correlate very well with flow cytometry results [10] and it is simple and quick; however, the reagent is expensive. Our main aim of this study was to standardize an in-house clot based screening method for MP detection which would not only be efficient but also inexpensive.
Materials and methods

Blood sampling
Blood samples of 25 healthy women with no history of illness or medical conditions and 25 women suffering from recurrent pregnancy loss from our earlier study who had elevated PS expressing MPs were taken for this study. Blood was immediately mixed gently with one tenth volume of 0.129 M sodium citrate. The citrated samples were first centrifuged twice at 1500 g for 15 min to obtain platelet free plasma. 400 μL aliquots of supernatant were made and stored at -80 °C until use.
Four different methods of MP assessment were performed and the results were correlated.
Flow cytometry: Flow cytometry was standardized in the laboratory by participating in the International Society of Thrombosis and Haemostasis workshop [7] . Briefly, 30 μL platelet free plasma was labeled with 10 μL annexinV-fluorescein isothiocyanate (FITC) (BD Biosciences, USA) and incubated in the dark for 30 min, after which 500 μL of annexinV binding buffer and 30 μL of flow count beads (FlowCount ™ Fluorospheres; Beckman-Coulter, USA) was added to obtain absolute MP counts. Appropriate controls were used to establish thresholds. The procedure was carried out as described earlier [5] . Using this method, we selected 25 samples which showed normal annexinV binding MP levels and 25 samples which showed elevated annexinV binding MP levels ( ≥ 2 standard deviation [SD] of mean of controls). Normal MP levels have been found in our earlier study while standardizing the MP assessment on BD FACS Aria in our laboratory [5] . We have assessed 75 healthy controls with no clinical illness and the mean±SD was found to 1894.7±488.52 MPs/μL of plasma.
Commercial STA Procoag PPL clotting time (CT) assay (Diagnostica Stago, France): This method detects procoagulant activity based on the principle that procoagulant MPs will shorten the activated factor X CT. Briefly, 25 μL of platelet free plasma is added with 25 μL of re agent 1: procoagulant phospholipid depleted plasma in cuvette and incubated for 60 s, after which 100 μL of reagent 2: activated factor X with calcium is added and clotting time is noted. All clotting assays were carried out on a semi-automated coagulometer (Diagnostica Stago STart 4, France).
Simple recalcification time:
This was a simple recalcification time which was done on the semi-automated coagulometer as follows: The preparation of MP rich and poor plasma is as given below. The test measures the CT after the addition of calcium chloride to MP rich plasma; after incubation with RVV and MP poor plasma. RVV activates factor X, thus triggering the coagulation cascade downstream of factor Xa. This eliminates the influence of factors upstream and also shortens the CT. The MP poor plasma which is actually platelet and MP free plasma, acts just like a factor deficient plasma in factor assays, making the test dependent on procoagulant phospholipid on MPs in the samples. The principle is similar to that of the commercial reagent. However, instead of directly using activated factor Xa with calcium, we used RVV (0.005 mg/mL) to activate factor X. The technique was done initially by using different concentrations of RVV; 0.005 mg/mL seemed to the most appropriate concentration for both shortening the clot time as well as detecting plasma samples with borderline elevated MP levels.
Preparation of MP rich plasma and MP poor plasma
The 400 μL aliquots of supernatant platelet free plasma are further spun at 13,000 g for 10 min; the bottom 200 μL plasma was the MP rich plasma used. The same centrifugation step was used to obtain phospholipid free plasma. For this, the blood samples of 20 healthy controls with normal prothrombin time and activated partial thromboplastin time and no factor deficiencies were taken and after the 13,000 g spin, 100 μL supernatant of all the aliquots were pooled and MP levels by flow cytometry were detected which was found to be negligible.
Ethics Committee approval
The study was approved by the Institutional Ethics Committee Review Board for Research on Human Subjects in accordance with the Declaration of Helsinki and written informed consent was obtained from all participants.
Statistical analysis
The correlation equation graph was made using Microsoft excel and Pearson correlation coefficient and coefficient of determination R 2 was calculated using Graph Pad Prism 5.0 software. Bland-Altman analysis was also done to compare the results of the STA Procoag PPL assay and the RVV assay using Graph Pad Prism 5.0 software. Statistical significance was assumed at p < 0.01, 95% confidence interval (CI). 
Results
The flow cytometry method was used to select the appropriate samples for standardizing the in-house method and the results were cross checked by the commercial STA Procoag PPL assay. Good correlation was seen with the results obtained by flow cytometry (R 2 = 0.88, p < 0.01). The CT obtained by the in-house clot assay significantly correlated with the results of those obtained by flow cytometry (R 2 = 0.87, p < 0.01). The patients were divided in five categories based on the AnnexinV binding MP levels and the clotting times observed by different techniques are as given in Table 1 . Figure 1 The Bland-Altman analysis done to compare the results of the STA Procoag PPL assay and the RVV assay showed a bias of -14.6 which favors the RVV assay towards having a shorter clotting time and was consistent for all samples tested as shown in Figure 2 .
The reagent cost of the three different methods without taking into consideration the cost of trained operators and machinery (flow cytometer, coagulometer, centrifuge), comes to approximately 39 US dollars for flow cytometer method (which includes the rainbow beads, CST beads, megamix beads; required for calibration, standardization and gating; FITC-annexin V and counting beads), 19 US dollars for STA Procoag PPL assay and 2 US dollars for the RVV test. The low cost of the RVV test is because of the need of only two reagents, the cost of 0.4 mg in 1 mL RVV being 95 US dollars, thus 0.005 mg/mL being 1.2 dollars.
Discussion
Cell-derived procoagulant MPs are emerging as important biomarkers in many facets of medicine. It is essential to thus standardize a simple, cost effective, quick and efficient screening test for detecting elevated MPs. Diagnostica Stago's STA Procoag PPL reagent has come close to achieving this; the only drawback being its cost.
It is important to note that three different functional assays are being compared to a flow cytometry method which is not a functional assay as seen in Table 1 and Figure 1 where in MP levels are being compared to the procoagulant activity. Flow cytometry is said to be the best technique as it gives the absolute MP numbers in plasma, the cellular origin and the main point being because of the precise gating of known size beads; it is for sure that we are detecting MP of the required size range. The only drawback is that though it detects the number of PS expressing MPs, it does not detect the functional activity of MPs. However, a good correlation of the MP levels was seen with the functional assays (R 2 = 0.87, p < 0.01).
From the observed results, elevated MP levels are easily detected by our in-house RVV test. Patient samples could then be further analyzed by flow cytometry to measure the number of MPs and cellular origin, if necessary. The cost of the test is minimal because of the low concentration of RVV required, especially when compared to the cost of activated factor Xa used in the STA Procoag PPL test. Our in-house RVV method still requires the availability of a coagulation analyzer and trained operators, which is not by any means inexpensive or trivial. However, the same is true for the other methods too. Thus the cost is considerably less expensive on comparison with the other methods.
The limitations of this study are that not all procoagulant markers were tested by flow cytometry and samples were from only one type of patient population. More samples with elevated PS and TF expressing MPs in different disease states needs to be analyzed. It is important to note that in this preliminary study, only the procoagulant MPs are detected and measured by these functional assays and the CT obtained has been correlated with PS expressing MPs detected by flow cytometry. However, it is known that there also exist PS negative MPs [11] which will not be detected by the annexinV flow cytometry test. PS negative MPs such as MPs expressing tissue factor (TF) may also aid in shortening the CT in these methods. For the same, further studies need to be done. However, the aim of this test as well as the STA Procoag test is to detect procoagulant MPs which they do. Thus these tests should be used only in thrombosis complicated clinical settings.
Conclusions
Though preliminary, the in-house clot based assay seems to be efficient, inexpensive and promising. It could definitely be considered as a routine cost-efficient screening test for procoagulant MP assessment in various thrombosis complicated diseases.
